相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploiting polypharmacology for drug target deconvolution
Taranjit Singh Gujral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Luca Mologni et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Tumor adaptation and resistance to RAF inhibitors
Piro Lito et al.
NATURE MEDICINE (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
P. Ballerini et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Arvin C. Dar et al.
NATURE (2012)
Chipping away at the lung cancer genome
William Pao et al.
NATURE MEDICINE (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
THYROID CANCER IN 2010 A roadmap for targeted therapies
Francesca Carlomagno et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Mammal-restricted elements predispose human RET to folding impairment by HSCR mutations
Svend Kjaer et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Transforming fragments into candidates: small becomes big in medicinal chemistry
Gerdien E. de Kloe et al.
DRUG DISCOVERY TODAY (2009)
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474
Francesca Carlomagno et al.
ENDOCRINE-RELATED CANCER (2009)
Challenges of fragment screening
Diane Joseph-McCarthy
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States
Irina Kufareva et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Synthesis, Modeling, and RET Protein Kinase Inhibitory Activity of 3-and 4-Substituted β-Carbolin-1-ones
Raffaella Cincinelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors
R. Graham Robinett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones
Eleonora Rizzi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
A decade of fragment-based drug design: strategic advances and lessons learned
Philip J. Hajduk et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno et al.
ONCOGENE (2004)
Fragment-based lead discovery
DC Rees et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
C Pargellis et al.
NATURE STRUCTURAL BIOLOGY (2002)
分享论文
